Related Experiment Video
Updated: May 23, 2026
26:48
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Autoimmune epilepsy: clinical characteristics and response to immunotherapy
Amy M L Quek1, Jeffrey W Britton, Andrew McKeon
1Department of Laboratory Medicine and Pathology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA.
Archives of Neurology
|March 28, 2012
Summary
Early immunotherapy can significantly improve seizure control in autoimmune epilepsy. Prompt treatment, especially for voltage-gated potassium channel complex antibody-positive patients, leads to better outcomes.
Area of Science:
- Neurology
- Immunology
- Epileptology
Background:
- Autoimmune epilepsy presents with diverse clinical and electroencephalographic findings.
- Identifying autoimmune etiology is crucial for appropriate treatment and improved outcomes.
- Many patients with autoimmune epilepsy are refractory to standard antiepileptic drugs.
Purpose of the Study:
- To characterize clinical features of autoimmune epilepsy.
- To evaluate the efficacy of immunotherapy in patients with autoimmune epilepsy.
- To identify predictors of immunotherapy response in autoimmune epilepsy.
Main Methods:
- Retrospective case series of 32 patients with suspected autoimmune epilepsy.
- Analysis of clinical presentation, autoantibody status, and response to immunotherapy (steroids, IVIG, cyclophosphamide, plasmapheresis).
- Seizure frequency was the primary outcome measure.
Main Results:
- 81% of patients showed improvement with immunotherapy; 18 became seizure-free.
- Early immunotherapy initiation (median 4 months) correlated with better response.
- Voltage-gated potassium channel complex antibody-positive patients consistently benefited from immunotherapy.
Conclusions:
- Early immunotherapy is effective for medically intractable epilepsy with suspected autoimmune etiology.
- Prompt treatment can significantly improve seizure outcomes.
- Identifying specific autoantibodies aids in predicting treatment response.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:19Encephalitis l: Introduction
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...